Clinical Trial Update: A Study of TAS1440 With ATRA in Subjects With r/r AML [Phase 1]

View source ↗

Summary

A Phase 1 study of TAS1440 in combination with all-trans retinoic acid for relapsed or refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ATRA (all-trans retinoic acid)
• TAS1440

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED